1. Home
  2. ALXO vs BSL Comparison

ALXO vs BSL Comparison

Compare ALXO & BSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.79

Market Cap

205.9M

Sector

Health Care

ML Signal

HOLD

Logo Blackstone

BSL

Blackstone

HOLD

Current Price

$12.92

Market Cap

169.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALXO
BSL
Founded
2015
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
205.9M
169.3M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ALXO
BSL
Price
$1.79
$12.92
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$3.50
N/A
AVG Volume (30 Days)
1.4M
41.8K
Earning Date
05-08-2026
01-01-0001
Dividend Yield
N/A
9.55%
EPS Growth
26.36
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$12.45
52 Week High
$2.66
$14.35

Technical Indicators

Market Signals
Indicator
ALXO
BSL
Relative Strength Index (RSI) 54.99 43.74
Support Level $1.54 $12.82
Resistance Level $2.27 $12.98
Average True Range (ATR) 0.12 0.08
MACD 0.03 0.00
Stochastic Oscillator 97.62 53.73

Price Performance

Historical Comparison
ALXO
BSL

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

About BSL Blackstone

Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.

Share on Social Networks: